Skip to main content
199 search results for:

GLP-1 agonists 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 02-08-2023 | Heart failure | News | Article

    Meta-analysis shows mixed picture for GLP-1 receptor agonists in heart failure

    A meta-analysis suggests that glucagon-like peptide-1 receptor agonists may help prevent new-onset heart failure in people with type 2 diabetes.

  2. 09-12-2022 | GLP-1 agonists | Ask the expert | Article

    Initiating GLP-1 receptor agonists: Managing side effects

    Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.

  3. 10-04-2022 | Healthcare costs | News | Article

    First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

    The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

  4. 02-24-2022 | GLP-1 agonists | Teaser

    GLP-1 receptor agonists

    Browse the latest news, clinical trial updates, and expert commentary.

  5. 05-20-2022 | Cardiovascular outcomes | News | Article

    Survival time analysis shows CV benefits of GLP1 receptor agonists

    Glucagon-like peptide-1 receptor agonists may delay the incidence of major adverse cardiovascular events by an average of 0.6 months over a 4-year period in people with type 2 diabetes, meta-analysis data suggest.

  6. 05-26-2022 | Insulin glargine | News | Article
    News in brief

    Real-world support for adding Gla-300 to GLP-1 receptor agonists in type 2 diabetes

    The addition of insulin glargine 300 units/mL to glucagon-like peptide-1 receptor agonist therapy in people with type 2 diabetes results in improved glycemic control without increasing risk for hypoglycemia, suggest findings from the real-world DELIVER-G study.

  7. 02-25-2022 | GLP-1 agonists | News | Article

    Real-world weight loss with GLP-1 receptor agonists lags behind clinical trials

    Only a third of people given a glucagon-like peptide-1 receptor agonist in clinical practice lose a clinically meaningful amount of weight, potentially due to high rates of discontinuation, say researchers.

  8. 02-04-2022 | Cardiovascular outcomes | News | Article

    Real-world data support SGLT2 inhibitors, GLP-1 receptor agonists for primary CVD prevention

    Data from primary care suggest that use of sodium-glucose cotransporter2 inhibitors, and possibly glucagon-like peptide-1 receptor agonists, may reduce the risk for cardiovascular disease events in people with type 2 diabetes without previous events.

  9. 09-29-2021 | EASD 2021 | News | Article

    SUSTAIN 10 analysis supports additive benefits of GLP-1 receptor agonists, SGLT2 inhibitors

    A post-hoc analysis of SUSTAIN 10 indicates that people with type 2 diabetes stand to gain from GLP-1 receptor agonist use even if they are already using an SGLT2 inhibitor.

  10. 12-21-2020 | Dulaglutide | News | Article

    Longer treatment persistence with dulaglutide vs other GLP-1 receptor agonists in type 2 diabetes

    Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.

  11. 04-23-2020 | GLP-1 agonists | News | Article

    Real-world evidence for renoprotective effects of GLP-1 receptor agonists

    People with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists have a lower risk for serious renal adverse events than those given dipeptidyl peptidase-4 inhibitors, indicate results from a Scandinavian real-world study.

  12. 01-09-2020 | Stroke | News | Article

    REWIND supports stroke protective effect for GLP-1 receptor agonists

    “[G]iven the frequency of stroke in people with diabetes, the severity of its associated morbidity, and the paucity of preventive therapies, the findings of this study suggest that GLP-1 receptor agonists should be considered when developing future stroke prevention guidelines for people with diabetes,” they write in The Lancet Diabetes & Endocrinology .

  13. 01-13-2020 | SGLT2 inhibitors | News | Article

    Lower gout risk with SGLT2 inhibitors vs GLP-1 receptor agonists

    People with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors are less likely to develop gout than those given glucagon-like peptide-1 receptor agonists, researchers report.

  14. 08-19-2019 | GLP-1 agonists | News | Article

    Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

    Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

  15. 08-31-2018 | GLP-1 agonists | Review | Article

    Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

    The aim of the present review is the assessment of the effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors, and major

  16. 10-17-2017 | GLP-1 agonists | Feature | Article

    GLP-1 receptor agonists: Cardiovascular trials and triumphs

    With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

  17. 12-08-2017 | Cardiovascular outcomes | News | Article

    Meta-analysis may support cardioprotective class effect for GLP-1 receptor agonists

    A meta-analysis published in The Lancet Diabetes & Endocrinology is suggestive of a class cardioprotective effect for the glucagon-like peptide-1 receptor agonists.

  18. 06-23-2018 | Cardiovascular outcomes | Review | Article

    Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

    Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

  19. 04-05-2018 | Oral combination medications | Review | Article

    Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: Symbiotic effects on metabolism and cardiorenal risk

    Goncalves E, Bell DSH. Diabetes Ther 2018; 9: 919–926. doi: 10.1007/s13300-018-0420-6

  20. 06-20-2018 | Cardiovascular outcomes | Article

    Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials

    Wang Q et al. Diabetes Res Clin Prac 2018; 143: 34–42. doi: 10.1016/j.diabres.2018.06.009

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.